

Special Issue

Tumor Antigen-Based Anticancer Vaccine and Immunotherapy

Message from the Guest Editor

Anti-cancer vaccines and immunotherapies are the most recent and successful strategies against cancer. Since the early 2000s, focused target therapy has replaced non-selective cytotoxic chemotherapy, leading to significant advancements in cancer treatment. Small interfering molecules and monoclonal antibodies have effectively modulated immune responses but have limited contribution to the active immune response, which is the goal of immunotherapy. This Special Issue focuses on research activities addressing the transformation of immunologically inert tumors into immunologically reactive cancers suitable for specific control or elimination from the host immune system. We welcome manuscripts addressing critical in vitro and in vivo issues to optimize strategies, from identifying tumor-specific antigens and tumor-associated antigen epitopes to exploring immune checkpoint inhibitors.

Guest Editor

Dr. Franco M. Buonaguro

Istituto Nazionale Tumori–IRCCS Fondazione Pascale, Napoli, Italy

Deadline for manuscript submissions

closed (28 February 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/208025

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).